Lineage Cell Therapeutics
LCTX
LCTX
59 hedge funds and large institutions have $114M invested in Lineage Cell Therapeutics in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
39% less call options, than puts
Call options by funds: $207K | Put options by funds: $339K
Holders
59
Holding in Top 10
1
Calls
$207K
Puts
$339K
Top Buyers
| 1 | +$15.1M | |
| 2 | +$5.98M | |
| 3 | +$4.78M | |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$4.78M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$796K |
Top Sellers
| 1 | -$857K | |
| 2 | -$389K | |
| 3 | -$291K | |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$220K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$117K |